<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824901</url>
  </required_header>
  <id_info>
    <org_study_id>E2512</org_study_id>
    <secondary_id>NCI-2012-01940</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E2512</secondary_id>
    <nct_id>NCT01824901</nct_id>
  </id_info>
  <brief_title>Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I/II trial studies the side effects and best dose of fibroblast growth
      factor receptor (FGFR) inhibitor AZD4547 when given with docetaxel and to see how well it
      works in treating patients with recurrent non-small cell lung cancer. Drugs used in
      chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. FGFR inhibitor AZD4547 may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is
      not yet known whether docetaxel and FGFR inhibitor AZD4547 are more effective when given
      together or separately.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determination of a recommended phase II dose for the combination of docetaxel and AZD4547
      (FGFR inhibitor AZD4547). (Phase I) II. Estimation and comparison of progression-free
      survival (PFS) of each treatment arm. (Phase II)

      SECONDARY OBJECTIVES:

      I. Pharmacokinetic evaluation of docetaxel with or without concomitant AZD4547.
      Pharmacokinetic evaluation of AZD4547 with concomitant docetaxel. (Phase I) II. Safety
      assessment and toxicity characterization of the combination. (Phase I) III. Initial
      assessment of clinical activity of the combination. (Phase I) IV. Response rate. (Phase II)
      V. Overall survival. (Phase II) VI. Estimation of response to single agent AZD4547 among
      patients who crossover from single agent docetaxel. (Phase II) VII. Further safety assessment
      and toxicity characterization of AZD4547 alone and in combination with docetaxel. (Phase II)

      OUTLINE: This is a phase I, dose-escalation study of FGFR inhibitor AZD4547 followed by a
      randomized phase II study.

      PHASE I:

      Patients receive docetaxel intravenously (IV) over 60 minutes on day 1 and FGFR inhibitor
      AZD4547 orally (PO) twice daily (BID) on days 2-15 of course 1 and days 1-14 of all
      subsequent courses. Courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity.

      PHASE II, STEP I: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21
      days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
      Patients who experience progressive disease may then receive FGFR inhibitor AZD4547 PO BID on
      days 1-14.

      ARM II: Patients receive docetaxel IV as in Arm I and FGFR inhibitor AZD4547 PO BID on days
      1-14.

      In both arms, courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity.

      PHASE II, STEP II:

      Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 3 years.

      This study opened to accrual on September 19, 2013 and was suspended to accrual on January
      29, 2014 after each of the first two patients had been registered to the first dose level of
      the phase I and experienced dose limiting toxicities (DLTs) during week 1 of cycle 1. The
      study was subsequently terminated on April 17, 2014 after having met the predefined criteria
      for closure per the phase I study design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">July 9, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547</measure>
    <time_frame>Assessed during cycle 1 (21 days)</time_frame>
    <description>A total of 3 dose levels of AZD4547 were planned: 40mg (level 1), 60mg (level 2), and 80mg (level 3) in combination with a standard dose of docetaxel (75mg/m^2). The starting dose level of AZD4547 was 40 mg. This portion of the study used a standard 3+3 design with patients enrolled in cohorts of 3. The plan was to recommend the maximum tolerated dose (MTD) as the dose level to be used in the phase II portion of the study. MTD is defined as the highest dose level at which less than or equal to 1 of 6 subjects experience dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (docetaxel; phase II step I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (docetaxel and AZD4547; phase II step I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II step II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Arm I (docetaxel; phase II step I)</arm_group_label>
    <arm_group_label>Arm II (docetaxel and AZD4547; phase II step I)</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>NSC 628503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4547</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Arm II (docetaxel and AZD4547; phase II step I)</arm_group_label>
    <arm_group_label>Phase II step II</arm_group_label>
    <other_name>NSC 765338</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase I:

        Inclusion Criteria:

          -  All females of childbearing potential must have a blood test or urine study within 2
             weeks prior to registration to rule out pregnancy

          -  Women of childbearing potential and sexually active males must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation; should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately

          -  Measurable or non-measureable disease based on Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease
             must be obtained =&lt; 4 weeks prior to registration

          -  Histologically or pathologically confirmed squamous NSCLC; patients whose tumors
             contain mixed NSCLC histologies are eligible if squamous morphology is predominant;
             mixed tumors with small cell anaplastic elements are not eligible

          -  Life expectancy &gt;= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1

          -  Adequate organ and marrow function

          -  Mean resting corrected QT interval (QTc) &lt; 470 msec obtained from 3 consecutive
             electrocardiograms

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Clinically important abnormalities in rhythm, conduction or morphology of resting
             electrocardiogram (ECG) e.g. complete left bundle branch block, third degree heart
             block

          -  Factors that increase the risk of QTc prolongation or risk of arrhythmic events such
             as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT
             syndrome or unexplained sudden death under 40 years of age or any concomitant
             medication known to prolong the QT interval

          -  Prior treatment with docetaxel (except in the adjuvant setting), or AZD4547

          -  Prior treatment with any other chemotherapy, immunotherapy or anticancer agents within
             2 weeks prior to registration

          -  Current evidence or previous history of retinal pigmented epithelium detachment (RPED)

          -  Previous laser treatment or intra-ocular injection for treatment of macular
             degeneration

          -  Current evidence or previous history of dry or wet age-related macular degeneration

          -  Current evidence or previous history of retinal vein occlusion (RVO)

          -  Current evidence or previous history of retinal degenerative diseases (e.g.
             hereditary)

          -  Current evidence or previous history of any other clinically relevant chorioretinal
             defect

          -  Uncontrolled brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD4547, docetaxel or other agents used in the study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow
             the investigational drug, previous significant bowel resection, or any other
             significant gastrointestinal disorder that could, in the opinion of the Investigator,
             interfere with the absorption of AZD4547

          -  Major surgical procedure within 3 weeks prior to registration

          -  Grade 3 or higher peripheral neuropathy, as defined by the National Cancer Institute
             (NCI) Common Terminology Criteria for Adverse Events (CTCAE),version 4.02

          -  Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Known human immunodeficiency virus (HIV) with cluster of differentiation (CD)4 count
             is =&lt; 200 cell/mm^3 or receiving antiretroviral therapy due to potential unfavorable
             interactions of the agents with the study treatment

          -  Receiving any other investigational agents while on study

          -  Medications that are potent inhibitors of cytochrome P450, family 3, subfamily A,
             polypeptide 4 (CYP3A4), cytochrome P450, family 2, subfamily C, polypeptide 8
             (CYP2C8), cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), or
             substrates of CYP3A4 prior to the first dose of study treatment

        Phase II pre-registration:

          -  Patient must have paraffin-embedded tumor specimen available for submission for
             determination of fibroblast growth factor receptor 1(FGFR1) amplification status

        Phase II Step I - Randomization:

          -  Besides the eligibility criteria in Step I, patient must have positive tumor FGFR1
             gene amplification (score FISH6) as determined by an AstraZeneca approved central
             laboratory.

        Phase II Step II:

        Inclusion Criteria:

          -  Patient was randomized to docetaxel only on step 1 and progressed per RECIST v1.1
             criteria; registration to step 2 must occur within 4 weeks of
             confirmation/determination of disease progression

          -  Confirmed measurable disease based on RECIST 1.1; baseline measurements and
             evaluations of all sites of disease must be obtained =&lt; 4 weeks prior to registration

        Exclusion Criteria:

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Rudin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group (ECOG) Research Base</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445-7648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <results_first_submitted>December 15, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2016</results_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD4547</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened to accrual on September 19, 2013 and was suspended to accrual on January 29, 2014 after each of the first two patients had been registered to the first dose level of the phase I and experienced DLTs. The study was subsequently closed on April 17, 2014 after having met the predefined criteria for closure per study design.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I</title>
          <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
docetaxel: Given IV
AZD4547: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm I (Docetaxel; Phase II Step I)</title>
          <description>Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
docetaxel: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Arm II (Docetaxel and AZD4547; Phase II Step I)</title>
          <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
docetaxel: Given IV
AZD4547: Given PO</description>
        </group>
        <group group_id="P4">
          <title>Phase II Step II</title>
          <description>Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
AZD4547: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I</title>
          <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" lower_limit="56" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547</title>
        <description>A total of 3 dose levels of AZD4547 were planned: 40mg (level 1), 60mg (level 2), and 80mg (level 3) in combination with a standard dose of docetaxel (75mg/m^2). The starting dose level of AZD4547 was 40 mg. This portion of the study used a standard 3+3 design with patients enrolled in cohorts of 3. The plan was to recommend the maximum tolerated dose (MTD) as the dose level to be used in the phase II portion of the study. MTD is defined as the highest dose level at which less than or equal to 1 of 6 subjects experience dose limiting toxicity (DLT).</description>
        <time_frame>Assessed during cycle 1 (21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547</title>
          <description>A total of 3 dose levels of AZD4547 were planned: 40mg (level 1), 60mg (level 2), and 80mg (level 3) in combination with a standard dose of docetaxel (75mg/m^2). The starting dose level of AZD4547 was 40 mg. This portion of the study used a standard 3+3 design with patients enrolled in cohorts of 3. The plan was to recommend the maximum tolerated dose (MTD) as the dose level to be used in the phase II portion of the study. MTD is defined as the highest dose level at which less than or equal to 1 of 6 subjects experience dose limiting toxicity (DLT).</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">As the first two patients experienced DLTs at the lowest dose level of the study, the MTD could not be identified and the study was then closed after having met the predefined criteria for closure per study design.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every 3 weeks while on treatment and for 30 days after the end of treatment.</time_frame>
      <desc>Submission of late adverse events is required at follow-up visits up to 3 years.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I</title>
          <description>Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG-ACRIN Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

